Hospital

Albumin is a cost-effective predictor of intravenous immunoglobulin-resistance in young patients with Kawasaki disease.

HCV infection is mostly curable and treated with antiviral medications, which can clear the virus from the body.

The landscape of clinical trials in oncology is rapidly evolving, driven by increasing research efforts and advancements in the field of clinical research.

Institutional review boards and ethics committees have seen it as their main task in the past few decades to protect children from questionable studies; however, they are faced with a new challenge with pediatric drug development.

Population well-being was associated with cardiovascular disease morality and rates of conditions such as hypertension, diabetes, and obesity.

Clostridioides difficile infection can be difficult to treat, but increasing disease awareness can improve screening and treatment outcomes.

Drug-induced myopathy is an underdiagnosed adverse effect of treatment with hydroxychloroquine with unclear treatment interventions other than discontinuing the drug.

Pre-exposure prophylaxis of neutralizing SARS-CoV-2 monoclonal antibodies may be preventative against SARS-CoV-2 transmission, decreasing frequency of new infections and number of hospitalized patients who need antiviral therapies, thus lowering costs.

When a patient is engaged in the home by a team that includes a pharmacist resource, social determinants of health issues become more clear and the care team can help close the gaps.

Despite an increase in HIV and poorer clinical outcomes among migrant populations, the uptake of PrEP among these individuals has been understudied.

Expert Nikhil Palekar, MD, said that although the treatment is far from a cure, it is a vital first step toward other treatments for Alzheimer Disease.

Diagnostic technologies are advancing quickly, which may lead to therapeutics for age-related diseases to safely reduce chronic low-grade inflammation generated by the immune system.

Oncology pharmacy is best learned in real time with real oncologists and real patients.

Clinical pharmacy services became eligible for reimbursement by all health insurance in Germany; however, challenges persist in upscaling and sustaining these services.

The novel treatment may be able to generate new cardiac tissue to create a functional human heart muscle.

Trial shows an improved survival rate at 4 years when treated with the STRIDE regimen in comparison to treatment with sorafenib in patients with unresectable hepatocellular carcinoma.

Lecanemab-irmb is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer disease.

In a study of individuals with Medicare, the incidence of type 2 diabetes was associated with approximately $30,000 to $98,000 excess lifetime medical expenditures.

Pirtobrutinib is a non–covalent (reversible) BTK inhibitor, demonstrating a 73.3% overall response rate with a median follow-up of 19.4 months among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

mRNA-1345 is a vaccine indicated for the prevention of respiratory syncytial virus-associated lower respiratory tract disease and acute respiratory disease.

Nonpharmacologic and nonopioid treatments associated with improvements in pain and/or function that appear comparable to opioid treatments.

Despite recommendations for adults to receive lung cancer screenings, rates have remained low compared with other cancer screening programs.

The safety and efficacy of long-term benzodiazepine use beyond the recommended timeframe is not well understood.

More than half of the patients prescribed oral anticancer agents report persistent moderate-to-severe symptoms, despite receiving counseling on adverse effect management.

To slow the production of MCI and dementia, utilizing more ways of establishing the diagnoses for women can prevent the progression.

If finalized, the regulation would potentially reduce prescription nonadherence and accidental misuse.

Adalimumab-adaz HCF in the 100 mg/mL strength is approved for indications that are no longer covered exclusively for the reference Humira after July 2023.

Pharmacists can use their knowledge and professional judgment to educate patients about when it is appropriate to take these medications and when to avoid them.